Lynozyfic: A New Hope in Blood Cancer Treatment
Comparing with Existing Therapies Lynozyfic joins a growing field of bispecific antibody therapies recently approved for multiple myeloma, including Tecvayli from Johnson & Johnson and Elrexfio from Pfizer. All three drugs function using a similar dual-target mechanism. However, Regeneron claims that Lynozyfic’s molecular structure may offer superior targeting efficiency and a slightly more favorable safety profile. Nonetheless, like its competitors, Lynozyfic carries warnings about potential side effects, including neurotoxicity and cytokine release syndrome (CRS)—a condition in which the immune system becomes dangerously overactive.
